Clinical trials: AMD - Age-Related Macular Degeneration
Macular Degeneration
Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)…
- Trial name
- NCT00845273
- Testing
- Pegaptanib sodium
- Volunteers
- 3,538 people
- Sponsor
- Pfizer
Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
This is a prospective pilot study to evaluate the usability and applicability of a self monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age Related Macular…
- Trial name
- NCT01542866
- Testing
- Health Management Tool (HMT)
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy, Age Related Macular Degeneration
AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma
The purpose of this multi-center study is to evaluate the extent to which AI-assisted fundus image interpretation improves the diagnostic performance of ophthalmologists.
- Conditions
- Diabetic Retinopathy, Age Related Macular Degeneration, Retinal Vein Occlusion, Glaucoma
- Trial name
- NCT07318428
- Testing
- VUNO Med-Fundus AI
- Where
- 5 sites in South Korea
- Volunteers
- 10 people
- Sponsor
- Inje University
Age-related Macular Degeneration, Diabetic Macular Edema
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
Comparable data for bevacizumab and aflibercept are lacking, as are studies comparing the systemic levels of ranibizumab, bevacizumab, and aflibercept and their relative effects on circulating vascular endothelial growth factor.
- Conditions
- Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT02118831
- Testing
- Blood Sample Collection, Aflibercept, Bevacizumab
- Volunteers
- 56 people
- Sponsor
- California Retina Consultants
Retinal Disease, Corneal Disease
Tissue Studies of Human Eye Diseases
The purpose of this project is to diagnose and evaluate ocular and related tissues with various diseases such as conjunctival, corneal, uveal, vitreoretinal and optic nerve disorders, ocular degenerative, metabolic or genetic…
- Conditions
- Retinal Disease, Corneal Disease, Diabetic Retinopathy, Uveitis
- Trial name
- NCT00001310
- Where
- United States
- Volunteers
- 3,833 people
- Sponsor
- National Eye Institute (NEI)
Retinal Dystrophies, Age-related Macular Degeneration
Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases
Using an adaptive optics imaging device, retinal structures are observed in healthy and diseased subjects.
- Conditions
- Retinal Dystrophies, Age-related Macular Degeneration, Arterial Hypertension, Diabetes
- Trial name
- iPhot (NCT01546181)
- Where
- France
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Age-related Macular Degeneration, Stargardt Disease
Efficacy of Acupuncture in Macular Diseases
This is a single-arm study designed to assess the efficacy of acupuncture (Traditional Chinese Medicine) for chronic macular diseases of several types.
- Conditions
- Age-related Macular Degeneration, Stargardt Disease, Macular Dystrophy
- Trial name
- AMAD (NCT02255981)
- Testing
- Acupuncture and massage
- Where
- 2 sites in Colombia
- Volunteers
- 33 people
- Sponsor
- Escuela Neijing
Age Related Macular Degeneration, Central Retinal Vein Occlusion
Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I
Aflibercept is FDA approved and the same molecule is available as hyperosmolar for oncology (cost 800 USD for 4ml) and isoosmolar for Ophthalmology (cost 1,770 USD for 0.05ml injection).
- Trial name
- ZIV (NCT02173873)
- Testing
- ziv-aflibercept drug
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- Rafic Hariri University Hospital
Exudative Age-Related Macular Degeneration
Monocentric Retrospective Observational Study on Patients With Macular Degeneration
Main Objective: The main objective of this retrospective observational study was to describe the evolution of visual acuity measured on ETDRS (Early Treatment Diabetic Retinopathy Study) scale, for patients with exudative…
- Trial name
- ELOUAN (NCT02089503)
- Testing
- intravitreal injections of Lucentis
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Hospital St. Joseph, Marseille, France
AMD
Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners
This is a prospective, randomised, multi-site clinical trial testing the non-inferiority of community optometry follow-up of participants with QnAMD over 12 months
- Trial name
- FENETRE (NCT03893474)
- Testing
- OCT, Visual Acuity
- Where
- United Kingdom
- Volunteers
- 742 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Renal Function Disorder, Diabetic Macular Edema (DME)
Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients.
- Conditions
- Renal Function Disorder, Diabetic Macular Edema (DME), Neovascular Age Related Macular Degeneration
- Trial name
- NCT06929507
- Testing
- Intravitreal injection of Faricimab or Aflibercept 2 mg
- Where
- 2 sites in Greece
- Volunteers
- 60 people
- Sponsor
- University Hospital, Alexandroupolis
Retinitis Pigmentosa, Maculopathy, Age Related
High Resolution Retina Imaging
To increase the clinical experience of using the rtx1 camera in various retinal disorders and to follow the evolution of structural alterations during retinal diseases using adaptive optics imaging with the rtx1 camera
- Conditions
- Retinitis Pigmentosa, Maculopathy, Age Related, Macular Dystrophy, Macular Edema
- Trial name
- IHR (NCT04128150)
- Where
- 3 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Regional Blood Flow
Choroidal Blood Flow and Progression of Age-Related Macular Degeneration in the Fellow Eye in Patients With Unilateral Choroidal Neovascularisation
Age-related macular degeneration (AMD) is the chief cause of severe and irreversible loss of vision in developed countries. The prevalence of AMD increases dramatically with age.
- Trial name
- NCT00808197
- Testing
- ocular blood flow measurement
- Where
- Austria
- Volunteers
- 41 people
- Sponsor
- Medical University of Vienna
Choroidal Neovascularization, Macular Degeneration
Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration
Age-related macular degeneration (AMD) represents the most common cause of blindness in patients over the age of 60. The major cause of vision loss in this disease is due to the development of choroidal neovascular membrane…
- Trial name
- NCT00001615
- Testing
- Corticosteroid
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Eye Institute (NEI)
Age-Related Macular Degeneration, Diabetic Retinopathy
National Eye Institute Biorepository for Retinal Diseases
Background: To understand diseases of the retina and the eye, information is needed about people with and without such diseases. Researchers want to study these people and follow them over time.
- Conditions
- Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease
- Trial name
- NCT01496625
- Where
- United States
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Low Vision, Age Related Macular Degeneration
Eye Movement Rehabilitation in Low Vision Patients
Approximately 217 million people worldwide currently suffer from low vision, which impacts a broad range of activities of daily living and is associated with depression and increased mortality.
- Trial name
- NCT04929756
- Testing
- Visual Feedback
- Where
- 2 sites in United States
- Volunteers
- 106 people
- Sponsor
- Northeastern University
Age Related Macular Degeneration, Intermediate AMD
A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression
This is a multicentre retrospective and prospective cohort study with the goal to develop a well-characterised multimodal image database of eyes with intermediate AMD with and without early atrophy. The main objectives are: 1.
- Conditions
- Age Related Macular Degeneration, Intermediate AMD, Atrophy, Prediction
- Trial name
- INTERCEPT-AMD (NCT05698316)
- Testing
- Collection of both retrospective and prospective data collection in 3 visits.
- Where
- 25 sites in France, Germany and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Wet AMD
Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy
To obtain a genotypic analysis of patients with chronic exudative age-related macular degeneration noted to have subretinal or intraretinal edema despite continuous monthly Anti-VEGF therapy.
- Trial name
- NCT01310686
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- West Coast Retina Medical Group, Inc.
Retinal Disease, AMD
Cell Collection to Study Eye Diseases
Background: Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) all affect the retina, the light sensing area at the back of the eye.
- Conditions
- Retinal Disease, AMD, Retinal Degeneration, Retinitis Pigmentosa
- Trial name
- NCT01432847
- Where
- United States
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Age-Related Macular Degeneration
Patient-centred Smartphone AI for Protecting Vision in Macular Disease
Macular disease is the leading cause of blindness in the UK and age-related macular degeneration must undergo monitoring to determine if an injection into the eye is required that month [required in 50% of visits] - these…
- Trial name
- NCT05433766
- Where
- 2 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- OKKO Health